Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Melanoma 74Hodgkin Disease 56Lymphoma 22Sarcoma 13Neoplasm Metastasis 11Leiomyosarcoma 8Uveal Melanoma 7Neoplasms 7Skin Neoplasms 6Neuroblastoma 4Sarcoma, Synovial 3Recurrence 3Solitary Fibrous Tumors 2Sarcoma, Alveolar Soft Part 2Hematologic Diseases 2HIV Infections 2Thyroid Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1

Interventions

Cyclophosphamide 20Brentuximab Vedotin 20fludarabine 16Lenalidomide 13Rituximab 12Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7pirtobrutinib 6Doxorubicin 6Bortezomib 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4venetoclax 3nilotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hematologic Diseases × Dacarbazine × Clear all
NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Seagen Inc.

Phase 2 Completed
131 enrolled 28 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Seagen Inc.

Phase 1 Completed
51 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡